BioLife Solutions reports Q3 ContOps GAAP EPS (4c), consensus (9c)

Reports Q3 revenue $30.6M, consensus $25.54M. “I’m pleased to report our fourth consecutive quarter of sequential Cell Processing revenue growth and expansion of adjusted gross and adjusted EBTIDA margins,” said Roderick de Greef, BioLife Chairman and CEO. “With Q3 now in the books and with good visibility into Q4, we are increasing our projected 2024 Cell Processing revenues by $2M above our previous guidance. Adjusting for the absence of revenue from the sale of our SciSafe biostorage business, this puts the total revenue for 2024 in the range of $98.0M-$100.0M.”